JSR Corporation (Representative Director, CEO, President and Chief Executive Officer: Tetsuro Hori; hereinafter "JSR") hereby announces that its Board of Directors resolved on April 22, 2025 to establish a new company, JSR-01 Corporation (hereinafter "newly established company"), and to transfer its in vitro diagnostics and in vitro diagnostics materials businesses, including Medical & Biological Laboratories Co., Ltd. (President and Representative Director: Hiroki Ito) and JSR Life Sciences Corporation (President and Representative Director: Eiji Takamoto) will be transferred to the newly established company through an absorption-type company split, and all outstanding shares of the newly established company will be transferred to Tokuyama Corporation (Representative Director, President and Executive Officer: Hiroshi Yokota; hereinafter "Tokuyama").

Tokuyama has designated the "Electronics," "Health" and "Environment" fields as growth businesses in its Medium-Term Management Plan 2025, and has been working to transform its business portfolio, aiming to achieve a sales ratio of 60% or more in growth businesses by FY2030. Tokuyama has reached an agreement to transfer the shares of the new company, believing that the IVD business and IVD materials business, which are the businesses to be transferred this time, will contribute to further enhancement of corporate value as the core businesses in the "health" field of the company.

The new company is scheduled to be established on June 1 and the share transfer is scheduled to be executed on October 1.

JSR will continue to work aggressively to establish a solid business foundation and to continuously enhance its value as a company that is trusted by all stakeholders.